For the former adjuvant standard treatment with interferon alpha-2a and 2b, we evaluated in a similar approach the patient preferences towards toxicity in that adjuvant setting in a multicenter approach in German skin cancer centers (the “DeCOG GERMELATOX survey) (Kaehler et al. 2016). The gene discussed is IFNA2; the disease is skin cancer.